Definium Therapeutics (DFTX) Profit After Tax (2021 - 2026)
Definium Therapeutics' (DFTX) quarterly Profit After Tax came in at -$77.4 million in Q1 2026, down 231.09% year-on-year from $59.0 million in Q1 2025, and down 52.83% on a QoQ basis from -$50.6 million in Q4 2025.
Definium Therapeutics (DFTX) Profit After Tax (2021 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has 6 years of Profit After Tax data on file, last reported at -$77.4 million in Q1 2026.
- On a quarterly basis, Profit After Tax fell 231.09% year-over-year to -$77.4 million in Q1 2026; TTM through Mar 2026 was -$237.8 million, a 208.13% decrease from a year earlier, with the FY2025 full-year figure at -$183.8 million, down 69.86% from the prior year.
- Profit After Tax for Q1 2026 stood at -$77.4 million, down from -$50.6 million in the prior quarter.
- Over the last five years, Profit After Tax for DFTX reached as high as -$4.9 million in Q4 2022 and fell as low as -$77.4 million in Q1 2026.
- Historically, Profit After Tax has averaged -$30.7 million across 5 years, with a median of -$24.3 million in 2023.
- Across the five-year window, Profit After Tax surged 80.08% in 2024 and plunged 629.71% in 2025, its largest moves.
- Year by year, Profit After Tax stood at -$4.9 million in 2022, then sank by 395.57% to -$24.3 million in 2023, then plunged by 41.02% to -$34.3 million in 2024, then plunged by 47.73% to -$50.6 million in 2025, then tumbled by 52.83% to -$77.4 million in 2026.
- Per Business Quant data, the three most recent Profit After Tax figures were -$77.4 million in Q1 2026, -$50.6 million in Q4 2025, and -$67.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Definium Therapeutics | 4.47 Bn | 4.47 Bn | - | -77.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -77.36 Mn |
| Dec 31, 2025 | -50.62 Mn |
| Sep 30, 2025 | -67.07 Mn |
| Jun 30, 2025 | -42.74 Mn |
| Mar 31, 2025 | -23.37 Mn |
| Dec 31, 2024 | -34.27 Mn |
| Sep 30, 2024 | -13.68 Mn |
| Jun 30, 2024 | -5.86 Mn |
| Mar 31, 2024 | -53.91 Mn |
| Dec 31, 2023 | -24.30 Mn |
| Sep 30, 2023 | -17.51 Mn |
| Jun 30, 2023 | -29.41 Mn |
| Mar 31, 2023 | -24.80 Mn |
| Dec 31, 2022 | -4.90 Mn |
| Sep 30, 2022 | -16.49 Mn |
| Jun 30, 2022 | -16.96 Mn |
| Mar 31, 2022 | -18.45 Mn |
| Dec 31, 2021 | -16.45 Mn |
| Sep 30, 2021 | -17.58 Mn |
| Jun 30, 2021 | -44.55 Mn |